{"id":"placebo-for-liraglutide","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct drug action. Placebos are essential for blinded trial design to isolate the true therapeutic benefit of the active comparator.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:52.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials for liraglutide (GLP-1 receptor agonist for type 2 diabetes and obesity)"}]},"trialDetails":[{"nctId":"NCT06976619","phase":"PHASE2","title":"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-03","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":60},{"nctId":"NCT03260881","phase":"PHASE4","title":"Liraglutide Effects on Epicardial Fat Inflammatory Genes","status":"COMPLETED","sponsor":"University of Miami","startDate":"2018-09-01","conditions":"Type2 Diabetes, Coronary Artery Disease","enrollment":38},{"nctId":"NCT02944500","phase":"PHASE4","title":"Saxenda: Underlying Mechanisms and Clinical Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Obesity","enrollment":28},{"nctId":"NCT06361238","phase":"PHASE3","title":"Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-19","conditions":"Delirium, Postoperative","enrollment":260},{"nctId":"NCT04199728","phase":"PHASE1, PHASE2","title":"Use of a GLP-1R Agonist to Treat Opioid Use Disorder","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-10-18","conditions":"Opiate Substitution Treatment, Opioid-Related Disorders","enrollment":27},{"nctId":"NCT03115424","phase":"PHASE3","title":"Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-06-22","conditions":"Obesity","enrollment":46},{"nctId":"NCT04763564","phase":"PHASE2","title":"Efficacy of Liraglutide Therapy in Patients With IPAA","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-22","conditions":"Pouchitis, Irritable Pouch Syndrome","enrollment":8},{"nctId":"NCT03856047","phase":"PHASE2","title":"Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-03-01","conditions":"Overweight, Obesity","enrollment":706},{"nctId":"NCT04311411","phase":"PHASE1","title":"A Study of Tirzepatide in Overweight and Very Overweight Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-24","conditions":"Obesity, Overweight","enrollment":114},{"nctId":"NCT02953665","phase":"PHASE2","title":"Safety and Efficacy of Liraglutide in Parkinson's Disease","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-04-03","conditions":"Parkinson Disease","enrollment":63},{"nctId":"NCT01722266","phase":"PHASE3","title":"Liraglutide in the Treatment of Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":72},{"nctId":"NCT04324229","phase":"NA","title":"Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Turku University Hospital","startDate":"2020-02-07","conditions":"Gestational Diabetes","enrollment":80},{"nctId":"NCT03795701","phase":"NA","title":"To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity","status":"COMPLETED","sponsor":"Texas Tech University","startDate":"2019-01-08","conditions":"Obesity","enrollment":73},{"nctId":"NCT01508949","phase":"PHASE2","title":"Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":35},{"nctId":"NCT03712098","phase":"PHASE2","title":"Daily Liraglutide for Nicotine Dependence","status":"COMPLETED","sponsor":"Rebecca Ashare","startDate":"2018-11-29","conditions":"Smoking Cessation, Weight, Body","enrollment":40},{"nctId":"NCT03757130","phase":"PHASE1","title":"Multiple Ascending Dose Study of AMG 598 in Adults With Obesity","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-11-26","conditions":"Obesity","enrollment":50},{"nctId":"NCT02527200","phase":"PHASE3","title":"Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-11-09","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":56},{"nctId":"NCT04605861","phase":"PHASE3","title":"The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-08-18","conditions":"Obese, Overweight","enrollment":414},{"nctId":"NCT04074161","phase":"PHASE3","title":"Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-09-11","conditions":"Overweight, Obesity","enrollment":338},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT03101930","phase":"PHASE4","title":"Cardiovascular Effects of GLP-1 Receptor Activation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-05-01","conditions":"Obesity, PreDiabetes","enrollment":329},{"nctId":"NCT02344186","phase":"PHASE4","title":"Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Temple University","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT03523273","phase":"PHASE2","title":"Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity","status":"COMPLETED","sponsor":"Michael Camilleri, MD","startDate":"2017-11-29","conditions":"Obesity","enrollment":136},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02765399","phase":"PHASE4","title":"The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2015-02-01","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT02973321","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":296},{"nctId":"NCT01982630","phase":"PHASE1","title":"Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-07","conditions":"Diabetes Mellitus","enrollment":87},{"nctId":"NCT03038620","phase":"PHASE4","title":"Impact of Liraglutide 3.0 on Body Fat Distribution","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-01","conditions":"Obesity, Visceral, Cardiovascular Diseases, Fat Disorder","enrollment":235},{"nctId":"NCT02138045","phase":"NA","title":"Treatment of Diabetic Neuropathy With Liraglutide","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus","enrollment":39},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT03480022","phase":"PHASE3","title":"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS","status":"COMPLETED","sponsor":"Woman's","startDate":"2018-09-26","conditions":"Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android","enrollment":88},{"nctId":"NCT04057261","phase":"PHASE3","title":"Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2020-11","conditions":"Type 2 Diabetes, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT02299388","phase":"PHASE4","title":"To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2014-10","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease","enrollment":11},{"nctId":"NCT03279731","phase":"PHASE3","title":"Binge Eating Liraglutide Intervention","status":"TERMINATED","sponsor":"Kelly Allison","startDate":"2017-09-29","conditions":"Binge-Eating Disorder","enrollment":36},{"nctId":"NCT02964247","phase":"PHASE3","title":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":303},{"nctId":"NCT02617654","phase":"PHASE2","title":"Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes","status":"COMPLETED","sponsor":"Per-Ola Carlsson","startDate":"2015-11","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT03341429","phase":"PHASE4","title":"Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-08-22","conditions":"Obesity","enrollment":70},{"nctId":"NCT01795248","phase":"PHASE4","title":"The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes","status":"COMPLETED","sponsor":"Tina Vilsboll","startDate":"2012-07","conditions":"Gestational Diabetes Mellitus","enrollment":105},{"nctId":"NCT04122716","phase":"PHASE4","title":"Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","status":"UNKNOWN","sponsor":"Signe Torekov","startDate":"2016-09","conditions":"Obesity","enrollment":215},{"nctId":"NCT04525300","phase":"PHASE3","title":"Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-05-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT04487743","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-05-09","conditions":"Obesity","enrollment":300},{"nctId":"NCT03449654","phase":"PHASE4","title":"Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2017-10-26","conditions":"Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT02650206","phase":"PHASE1","title":"Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-01","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset","enrollment":56},{"nctId":"NCT02918279","phase":"PHASE3","title":"Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-29","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":251},{"nctId":"NCT02963935","phase":"PHASE3","title":"Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-02-06","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":282},{"nctId":"NCT03486392","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-26","conditions":"Obesity","enrollment":474},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT04008290","phase":"PHASE4","title":"The Effect of Liraglutide on the GIT","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-04-01","conditions":"Obesity","enrollment":15},{"nctId":"NCT02911818","phase":"PHASE4","title":"Lifestyle Modification and Liraglutide","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-09","conditions":"Obesity","enrollment":150},{"nctId":"NCT02928471","phase":"","title":"Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":200},{"nctId":"NCT02910570","phase":"PHASE4","title":"Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis","status":"COMPLETED","sponsor":"Parker Research Institute","startDate":"2016-11","conditions":"Osteoarthritis, Knee","enrollment":150},{"nctId":"NCT02905864","phase":"PHASE4","title":"Liraglutide 3 mg for Knee Osteoarthritis","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":150},{"nctId":"NCT02928679","phase":"PHASE4","title":"Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":150},{"nctId":"NCT02931383","phase":"PHASE4","title":"Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":150},{"nctId":"NCT02928614","phase":"PHASE4","title":"Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":150},{"nctId":"NCT02696148","phase":"PHASE1","title":"A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-14","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":24},{"nctId":"NCT02073929","phase":"PHASE4","title":"LIPT - Liraglutide in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Jens Faber","startDate":"2014-03","conditions":"Polycystic Ovary Syndrome, Cardiovascular Disease","enrollment":72},{"nctId":"NCT03426085","phase":"PHASE2","title":"The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Eastern Virginia Medical School","startDate":"2016-05","conditions":"Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication","enrollment":44},{"nctId":"NCT01870297","phase":"PHASE1","title":"A Study of LY3025876 in Participants With Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus","enrollment":72},{"nctId":"NCT02473809","phase":"PHASE4","title":"The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-08","conditions":"Diabetes Complications, Osteoporosis","enrollment":60},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT02870231","phase":"PHASE1","title":"Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-08-18","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":187},{"nctId":"NCT02660047","phase":"PHASE4","title":"Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2015-08","conditions":"Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease","enrollment":51},{"nctId":"NCT01572740","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-04-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":257},{"nctId":"NCT01272219","phase":"PHASE3","title":"Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06-01","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":3731},{"nctId":"NCT01505673","phase":"PHASE4","title":"Adding Liraglutide to High Dose Insulin: Breaking the Cycle","status":"COMPLETED","sponsor":"Ildiko Lingvay","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":71},{"nctId":"NCT01787916","phase":"PHASE4","title":"52 Week Trial of Liraglutide in Type 1 Diabetes","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2013-04","conditions":"Type 1 Diabetes","enrollment":15},{"nctId":"NCT01272232","phase":"PHASE3","title":"Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06-01","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":846},{"nctId":"NCT01557166","phase":"PHASE3","title":"Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06-07","conditions":"Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea","enrollment":359},{"nctId":"NCT00781937","phase":"PHASE3","title":"Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10-30","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":422},{"nctId":"NCT02647944","phase":"PHASE2","title":"Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-12-18","conditions":"Obesity","enrollment":40},{"nctId":"NCT01664247","phase":"PHASE3","title":"The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-10-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":346},{"nctId":"NCT02235961","phase":"PHASE1","title":"Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-09-04","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":163},{"nctId":"NCT02472717","phase":"PHASE2","title":"Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2015-05","conditions":"Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance","enrollment":""},{"nctId":"NCT01562678","phase":"PHASE4","title":"Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-03","conditions":"Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss","enrollment":28},{"nctId":"NCT01206101","phase":"PHASE2","title":"Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2012-03-21","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":3},{"nctId":"NCT00318461","phase":"PHASE3","title":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1091},{"nctId":"NCT00294723","phase":"PHASE3","title":"To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":746},{"nctId":"NCT01800968","phase":"PHASE2","title":"Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-04","conditions":"Acute Heart Failure","enrollment":300},{"nctId":"NCT02098395","phase":"PHASE3","title":"The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":835},{"nctId":"NCT00983021","phase":"PHASE1","title":"Safety and Tolerability of NN9068 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01536665","phase":"PHASE1","title":"The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-02","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":45},{"nctId":"NCT01937598","phase":"PHASE3","title":"Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D","status":"COMPLETED","sponsor":"Michael A. Nauck","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00761540","phase":"PHASE1","title":"To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10","conditions":"Diabetes, Healthy","enrollment":37},{"nctId":"NCT00943501","phase":"PHASE1","title":"Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":21},{"nctId":"NCT01511692","phase":"PHASE1","title":"Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":43},{"nctId":"NCT01620476","phase":"PHASE1","title":"Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-09","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01516255","phase":"PHASE1","title":"Effect of Liraglutide on Heart Frequency in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-07","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT01615978","phase":"PHASE1","title":"Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT01515592","phase":"PHASE1","title":"Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01508858","phase":"PHASE1","title":"Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":21},{"nctId":"NCT01509755","phase":"PHASE2","title":"Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":196},{"nctId":"NCT01789086","phase":"PHASE1","title":"A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-02","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":21},{"nctId":"NCT01516476","phase":"PHASE2","title":"Study of RO6807952 in Patients With Diabetes Mellitus Type 2","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Diabetes Mellitus Type 2","enrollment":2},{"nctId":"NCT02930265","phase":"NA","title":"Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-09","conditions":"Ischemic Cardiomyopathy","enrollment":400},{"nctId":"NCT01733758","phase":"PHASE3","title":"A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 2","enrollment":494},{"nctId":"NCT02408705","phase":"PHASE2","title":"Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2015-01","conditions":"Type 1 Diabetes Mellitus","enrollment":14},{"nctId":"NCT02545738","phase":"PHASE4","title":"Antiproteinuric Effects of Liraglutide Treatment","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2015-04","conditions":"Diabetic Kidney Disease","enrollment":32},{"nctId":"NCT02057172","phase":"PHASE2","title":"Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":254},{"nctId":"NCT02783196","phase":"NA","title":"Effect of Liraglutide on Clock Genes","status":"UNKNOWN","sponsor":"Tel Aviv University","startDate":"2016-07","conditions":"Type 2 Diabetes","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":794,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for liraglutide","genericName":"Placebo for liraglutide","companyName":"Per-Ola Carlsson","companyId":"per-ola-carlsson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials for liraglutide (GLP-1 receptor agonist for type 2 diabetes and obesity).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}